Ironwood Pharmaceuticals Q1 2022 Investor Update

Ironwood Pharmaceuticals presented its Q1 2022 investor update on May 5, 2022, detailing strategic priorities around maximizing LINZESS sales, advancing its GI pipeline, and developing new treatments including CNP-104 for primary biliary cholangitis and IW-3300 for visceral pain conditions. The company outlined efforts to drive sustained profits and cash flow while strengthening intellectual property protection for its lead gastrointestinal franchise.